SEEd Medical Publishers

Ultima pubblicazione

Segni e sintomi inusuali o rari in Neurologia

Questa guida tascabile di facile consultazione fornisce al medico un supporto per identificare in modo corretto alcuni sintomi neurologici che, per la loro scarsa prevalenza o per la loro insorgenza bizzarra, sono difficili da riconoscere e possono quindi dare origine a diagnosi errate. Per ogni sintomo vengono riportati sinteticamente la descrizione fornita dal paziente, il suo significato clinico, la diagnosi e l’approccio terapeutico. Molti nuovi segni e sintomi arricchiscono questa edizione, nella quale tutte le terapie sono state aggiornate sulla base delle scoperte scientifiche degli ultimi anni.

Il più visto

L’emogasanalisi

L'emogasanalisi

L’obiettivo principale di questo Manuale è di permettere al lettore di eseguire e di interpretare in modo semplice e completo un’EGA, rendendolo competente e sicuro nella sua esecuzione e interpretazione. Per facilitare l’apprendimento, il Manuale è diviso in capitoli brevi, finalizzati ad un obiettivo da raggiungere. L’esposizione è strutturata in domande, algoritmi e flow chart per privilegiare la semplicità e le sequenze logiche. In ogni capitolo sono presenti quiz di autovalutazione, che consentono di testare la performance in progress e di mettere in pratica quanto appreso.
Budget Impact in Your Hand

Budget Impact in Your Hand

Transform your excel budget impact in an elegant and consistent App for your tablets and share safely personalized analyses.

Have a look

Ultimi articoli pubblicati

    LinkedIn Company Updates

  • 7 Days Agoview on linkedin

    SEEd Medical Publishers

    Hypokalemic periodic paralysis (HPP) is a kind of periodic paralysis, which is a heterogeneous group of muscle diseases. It is characterized by episodes of flaccid and sudden muscle weakness. Here, we present a case of HPP. The patient was referred to our department because of severe dizziness and fall. After a comprehensive evaluation, a markedly low potassium was detected. The patient’s symptoms resolved after replacement of potassium and he was discharged without deficits. Even though the literature reports an association with exercise, carbohydrate load, and stress, further workup in our patient revealed no association with these precipitants. A proper differential diagnosis should rule out other causes of weakness and paralysis, thus allowing a timely treatment. #health #vestibular #differentialdiagnosis #paralysis #Potassium #MuscleWeakness #Dizziness #Hypokalemia Aysun Işıklar https://lnkd.in/dSG6JMi

  • 17 Days Agoview on linkedin

    SEEd Medical Publishers

    BACKGROUND: Although the use of long-acting injectable antipsychotics (LAIs) is considered an important option in the management of schizophrenia two recent meta-analysis, which aimed to compare LAIs vs oral antipsychotics (OAPs) in terms of relapse rate, showed discordant results. AIM: To investigate factors affecting the efficacy of antipsychotics in terms of relapse prevention in the real-world and to estimate the management cost of an episode of relapse. CONCLUSION: SGA LAIs administered every 90 days seems to be the best option for the treatment of patient with schizophrenia from both the clinical and economic perspectives. #healtheconomics #relapseprevention; #Schizophrenia; #Relapse; #Italy; #Antipsychotics; @Orietta Zaniolo; Gianni Ghetti; Massimiliano Povero; Lorenzo Pradelli; AdRes s.r.l. Health Economics & Outcomes Research https://lnkd.in/dGR9s_x

  • 21 Days Agoview on linkedin

    SEEd Medical Publishers

    BACKGROUND: Access to Directly Acting Antivirals (DAAs) for Hepatitis C Virus (HCV) treatment in Italy was initially restricted to severe patients. In 2017, AIFA expanded access to all patients, to achieve elimination by 2030 AIM: To investigate the impact of different hospitals’ organizational models on elimination timing, treatment capacity and direct costs. RESULTS: The study calculated the average cost to treat HCV patients (~ € 1,470 per patient). Key cost drivers are lab tests (60%) and specialist visits (30%). Over one year, H&S can treat 68% more patients than CoE. As deferred patients absorb up to 40% of total costs, the “Optimized” model was designed by streamlining specialists’ visits and involving general practitioners during follow-up. “Optimized” model increases treatment capacity and reduces costs of deferred patients by 72% vs CoE. CONCLUSION: The study demonstrates the importance of organizational models in efficiently achieving 2030 elimination. #HCV; #Hepatitis; #EconomicEvaluation; #patients; Stefano Fagiuoli; LUISA Pasulo; Franco Maggiolo; Rosaria Spinella; Paolo Del Poggio; roberto boldizzoni; @Mariella Di Marco; Alessandro Aronica; @Chiara Benedetti; Paolo Correale; Chiara Garavaglia; Carlo Nicora https://lnkd.in/dMC7aVh

  • 24 Days Agoview on linkedin

Partner & Collaborazioni

Partners & Associations